Company Description
Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions in the United States.
The company offers orthopedic treatments using Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue).
Its lead product is GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
It offers Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting).
Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.
| Country | Israel |
| Founded | 2004 |
| IPO Date | Dec 4, 2025 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Ehud Geller |
Contact Details
Address: 60 Medinat Hayehudim, Entrance C Herzliya, 4676652 Israel | |
| Phone | 972 9 960 1917 |
| Website | regentis.co.il |
Stock Details
| Ticker Symbol | RGNT |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 1912966 |
| CUSIP Number | 001219096 |
| ISIN Number | IL0012190968 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Ehud Geller | Chief Executive Officer |
| Ori Gon | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | 6-K | Report of foreign issuer |
| Feb 5, 2026 | 6-K | Report of foreign issuer |
| Jan 29, 2026 | 6-K | Report of foreign issuer |
| Jan 20, 2026 | 6-K | Report of foreign issuer |
| Jan 6, 2026 | 6-K | Report of foreign issuer |
| Jan 6, 2026 | 6-K | Report of foreign issuer |
| Dec 18, 2025 | 6-K | Report of foreign issuer |
| Dec 5, 2025 | 6-K | Report of foreign issuer |
| Dec 4, 2025 | 424B3 | Prospectus |